Summary There are important interactions between prostatic tumours and bone. This study was designed to examine whether prostatic tissue can express bone inductive factors, in particular, the Bone Morphogenetic Proteins (BMPs). The polymerase chain reaction (PCR) has been used to screen Prostate cancer is the third most common malignancy in men in England and Wales (OPCS-Cancer Statistics, 1985). Of the 9,000 patients that present every year, approximately 50% are already suffering from metastatic disease, one of the major causes of their mortality (Whitmore, 1984 Thompson, 1990 ).
Prostate cancer is the third most common malignancy in men in England and Wales (OPCS-Cancer Statistics, 1985) . Of the 9,000 patients that present every year, approximately 50% are already suffering from metastatic disease, one of the major causes of their mortality (Whitmore, 1984) . Current investigative methods are still unable to predict with certainty which patients are likely to develop metastases. This often causes a dilemma for the clinician, and patients who might go on to develop bony metastases may chose to remain untreated, e.g. a simple observation and 'watch and wait' policy is adopted. However, the availability of luteinizing hormone releasing-hormone (LH-RH) analogues and antioestrogens mean that treatment modalities are now available for use in high-risk patients (Furr & Denis, 1988) . There is, therefore, a substantial need for criteria to define the metastatic potential of individual prostate cancers.
Prostate carcinomas frequently metastasise to bone and induce bone formation at specific sites, identifiable on X-ray as marked radiodense or osteosclerotic foci (Charhon et al., 1983) . These so-called osteoblastic metastases result from an imbalance in the rate of bone resorption and formation, with osteoblasts depositing bone at sites independent of osteoclast resorption. The mechanisms by which prostate tumour cells induce new bone formation have yet to be determined. One possibility is that the tumour cells secrete growth factors or cytokines which act locally to stimulate the proliferation and differentiation of osteoblasts. Human prostate cancer cells have been found to produce a variety of known growth factors including members of the fibroblast growth factor (FGF) and transforming growth factor-P (TGF-P) families, as well as transforming growth factor-x (TGF-ca) and epidermal growth factor (EGF) (Mydlo et al., 1988; Mori et al., 1990; Thompson, 1990 ).
An important group of bone-inducing factors are the bone morphogenetic proteins which have the capacity to induce new bone formation when implanted ectopically into experimental animals (Urist, 1965) . Seven BMPs have so far been identified and, with the exception of BMP-1, they are all members of the TGF-P superfamily (Celeste et al., 1990; Wozney et al., 1988; Wozney, 1989) . To date there has been no examination of BMP gene expression in prostatic tissue.
The aims of this study were 2-fold. Firstly, to establish whether prostatic tissue and prostatic cell lines expressed the genes for BMPs. Secondly, to examine the pattern of BMP expression in patients with benign prostatic hyperplasia, and metastatic and non-metastatic prostatic adenocarcinoma in order to determine whether any differences in expression were related to the tumorigenic and metastatic phenotype of the prostatic cancer. The expression of BMPs one to six has been determined by mRNA phenotyping (Brenner et al., 1989) utilising specifically designed oligonucleotide primers selected for non-homologous regions of the BMPs.
Materials and methods

Patients
Forty-one patients were studied. The study was approved by the ethics committee and informed consent was obtained from each patient prior to entering the study. Nineteen men had histologically proven prostatic adenocarcinoma, 11 of whom had skeletal metastases as shown by a positive technetium 99-m bone scan. Twelve patients had known benign prostatic hyperplasia (BPH) and 10 others had ocular melanomas and were used as controls, since ocular melanomas rarely metastasise to the bony skeleton and such metastases are a very late phenomenon. None of the 10 ocular melanoma patients had bony metastases. Prostatic tissue samples were obtained from transurethral resection specimens or by transrectal needle core biopsy, and ocular melanoma samples were obtained following enucleation. The nature of each sample was confirmed by standard histological examination, and graded using the Gleason scoring system (Gleason et al., 1974) . Samples were snap frozen in liquid nitrogen immediately after removal and stored at -70°C prior to RNA extraction.
Cell lines
Two well characterised mycoplasma-free human prostate cell lines, (Kaighn et al., 1979) and DU145 (Stone et al., 1978) Polymerase chain reaction cDNA was amplified by PCR using two specific oligonucleotide primers designed for specific gene sequences (Table I) . Since the BMPs show varying degrees of homology with each other, primers were designed to unique regions specific for the individual BMPs. Technical difficulties were enountered with the designed BMP-7 primers. Two different sets of primers for BMP-7 failed to produce a PCR product from a range of cDNAs tested. As they could not be validated, they were therefore excluded from this study. By using genomic DNA instead of cDNA in the PCR, introns were shown to be present for BMP-1, -3 and -6 but not for Results PCR amplification of cDNA from the 41 patients and from the two prostate cancer cell lines, PC3 and DU145 revealed that BMP-1 to 6 were expressed in prostatic adenocarcinoma, BMP-1 to 5 were expressed in benign prostatic hyperplasia and ocular melanoma, BMP-1 and 4 were expressed in DU145 cells and BMP-1, 2, 3, 4 and 6 were expressed in PC3 cells (Table II) . Serum starvation was not found to alter the pattern of BMP expression in the two cell lines. Examples of PCR results are shown in Figure 1 . Analysis of BMP expression in human tissue samples showed that BMP-6 was expressed only in patients with prostatic adenocarcinoma (32%). Table III shows the pattern of BMP expression in the patients with prostatic adenocarcinoma after sub-dividing them into two groups on the basis of a positive or negative bone scan. With the exception of BMP-5, which was expressed in all prostatic samples, there was an increase in the percentage of patients expressing each of the BMPs in the bone scan positive compared with the bone scan negative group. The proportion of patients with positive expression for BMP-2 and BMP-3 appeared to be nearly twice as high in patients with proven skeletal metastases. Most clearly, BMP-6 was expressed in 55% of patients with positive bone (89) 19 (100) Patients BMP-J BMP-2 BMP-3 BMP-4 BMP-5 BMP-6 Bone scan positive n = 11 11 (100) 8 (73) 5 (45) 11 (100) 11 (100) 6 (55) Bone scan negative n = 8 7 (88) 3 (38) 2 (25) 6 (75) 8 (100) 0 (0) scans and not in any of the eight bone scan negative patients. BMP expression did not appear to correlate with the grading of the tumour, using the Gleason scoring system.
Discussion
There have been many attempts to isolate factors from prostatic tissue that might stimulate osteoblast activity but the nature of the tumour derived factor(s) responsible for the osteogenic metastases has remained unclear (Jacobs et al., 1979; Simpson et al., 1985; Maehama et al., 1986; Koutsilieris et al., 1987; Story et al., 1987) . In this paper we have demonstrated that BMPs 1 to 6 are expressed in prostatic adenocarcinoma, and this suggests that the BMPs may have a role in the formation of skeletal metastases in prostate cancer. BMP-6 appears to be selectively expressed in bonescan positive metastatic disease. The recent availability of some of the BMPs in recombinant form has enabled the effects of individual BMPs to be studied in vivo. BMP-2 is the only member of the family so far shown to induce bone formation when administered alone , although BMP-3 and BMP-4 induce endochondral bone formation in rats when implanted in a carrier demineralised matrix (Luyten et al., 1989; Hammonds et al., 1991) . The increased incidence of expression of BMP-2, 3 and 4 in prostatic tissue from patients with a positive bone scan suggests that these may be candidates for the local osteoblast stimulatory factor(s). However, widespread expression of the BMPs in prostate cell lines, benign prostatic tissue, ocular melanomas and other human tissues as well implies that they may have other activities in addition to their bone morphogenetic properties. BMP-2 and Vgr-1 (the murine equivalent of BMP-6) expression has been observed in non-skeletal tissue in embryonic, newborn and adult mice and it has been suggested that the co-ordinated expression of these and other members of the TGF-P superfamily is required to control the progression of specific cell types through their differentiation pathways (Lyons et al., 1989) , and that BMP-2 plays multiple roles in morphogenesis and pattern formation in the vertebrate embryo (Lyons et al., 1990) . Human BMP-6 has been identified in placenta and brain cDNA libraries (Celeste et al., 1990) . Because of the apparent additional roles of the BMPs outside bone, it has been suggested that they are renamed DVR (decapentaplegic-Vgrelated) proteins after the first two members of this family to be identified (Lyons et al., 1991) .
The relationship between the presence of mRNAs for BMPs and the ability of that tissue to induce bone formation remains unclear. It has been established that BMP-2 requires post-translational processing, involving dimerisation and cleavage, analogous to the processing of TGF-P, to produce active BMP ) and this may be the case for the other BMPs. This process may be tissue dependent and mediated by extracellular proteases. It may be that the level of expression is important and is induced by certain as yet unknown factors. Action of the BMPs may be dependent upon the induction of specific receptors and specific, highaffinity cell-surface binding proteins have been demonstrated for BMP-4 (Paralkar et al., 1991) .
The observation that there is a correlation between BMP-6 expression and bone metastases in prostate cancer warrants further investigation. Although, from the data obtained it is not possible to relate BMP expression to the ability of the cancer cells to metastasise, it appears that BMP-6 expression is correlated with the presence of skeletal metastases. The nature of this relationship remains to be defined. In addition, the relationship between the presence of mRNA for BMP-6 in prostatic tissue and its putative role require further work to determine whether, like BMP-2, post-translational processing (dimerisation and cleavage) is required for active BMP-6 to be produced by the cell. Analysis of other tumours which produce osteoblastic metastases (breast, thyroid, lung) for BMP-6 expression may provide additional evidence for a relationship between BMP-6 expression and skeletal metastases. Such studies may ultimately enable the identification of sub-groups of patients with prostate cancer whose tumours have invasive and metastatic potential, allowing treatment to be directed at those most at risk of dying from this common malignancy.
